Mochida Pharmaceutical Co (TSE:4534) Cyclically Adjusted Revenue per Share: 円3,062.40 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4534 Mochida Pharmaceutical Co Ltd TSE:4534
63 GF Score
Price 円3,185.00
GF Value 円3,675.74
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Mochida Pharmaceutical Co TSE:4534 -0.31% 63 Cyclically Adjusted Revenue per Share is 円3,062.40 as of Mar. 2026. GuruFocus rates TSE:4534 with a GF Score™ of 63/100 and a GF Value™ of 円3,675.74 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Mochida Pharmaceutical Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円831.142. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円3,062.40 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Mochida Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 3.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Mochida Pharmaceutical Co was 4.80% per year. The lowest was 3.70% per year. And the median was 4.15% per year.

As of today (2026-07-28), Mochida Pharmaceutical Co's current stock price is 円3185.00. Mochida Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円3,062.40. Mochida Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 1.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mochida Pharmaceutical Co was 2.61. The lowest was 0.97. And the median was 1.38.


Mochida Pharmaceutical Co  (TSE:4534) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Mochida Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3185.00/3062.40
=1.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Mochida Pharmaceutical Co was 2.61. The lowest was 0.97. And the median was 1.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Mochida Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Mochida Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Mochida Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mochida Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Mochida Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,570.98 2,696.90 2,800.07 2,955.55 3,062.40

Mochida Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,955.55 2,981.91 3,004.88 3,045.68 3,062.40

TSE:4534 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mochida Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mochida Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mochida Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Mochida Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4534
63GF Score
Mochida Pharmaceutical Co Ltd TSE:4534
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mochida Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mochida Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=831.142/112.7000*112.7000
=831.142

Current CPI (Mar. 2026) = 112.7000.

Mochida Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 617.401 98.100 709.287
201609 551.924 98.000 634.713
201612 669.923 98.400 767.280
201703 612.320 98.100 703.450
201706 730.645 98.500 835.977
201709 644.127 98.800 734.748
201712 733.604 99.400 831.762
201803 580.143 99.200 659.094
201806 750.523 99.200 852.661
201809 690.988 99.900 779.523
201812 765.648 99.700 865.482
201903 558.906 99.700 631.782
201906 675.138 99.800 762.405
201909 637.819 100.100 718.104
201912 705.177 100.500 790.781
202003 584.051 100.300 656.257
202006 706.474 99.900 796.993
202009 625.629 99.900 705.790
202012 731.354 99.300 830.046
202103 602.151 99.900 679.303
202106 714.991 99.500 809.844
202109 696.308 100.100 783.955
202112 807.449 100.100 909.086
202203 672.437 101.100 749.591
202206 737.097 101.800 816.020
202209 681.540 103.100 745.001
202212 761.876 104.100 824.817
202303 596.774 104.400 644.219
202306 677.796 105.200 726.118
202309 688.657 106.200 730.806
202312 808.290 106.800 852.943
202403 695.335 107.200 731.010
202406 716.922 108.200 746.739
202409 724.634 108.900 749.920
202412 835.966 110.700 851.069
202503 689.064 111.100 698.988
202506 751.269 111.700 757.995
202509 799.831 112.000 804.830
202512 916.892 113.000 914.458
202603 831.142 112.700 831.142

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円3,062.40 mean?
Mochida Pharmaceutical Co (TSE:4534) has a Cyclically Adjusted Revenue per Share of 円3,062.40 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mochida Pharmaceutical Co and its competitors.
Is Mochida Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Mochida Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円3,062.40. Overall, Mochida Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mochida Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Mochida Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円3,062.40 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mochida Pharmaceutical Co and its competitors. Mochida Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円3,062.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mochida Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Mochida Pharmaceutical Co (TSE:4534) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,675.74, compared to a current price of 円3,185.00 — trading 13.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円3,062.40. Mochida Pharmaceutical Co's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Mochida Pharmaceutical Co (TSE:4534), the current Cyclically Adjusted Revenue per Share is 円3,062.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mochida Pharmaceutical Co (TSE:4534) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of 円3,185.00 is trading 13.4% below its estimated GF Value™ of 円3,675.74. GuruFocus considers Mochida Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4534:

  • Cyclically Adjusted Revenue per Share: 円3,062.40
  • GF Value™: 円3,675.74 vs. price of 円3,185.00 (13.4% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the TSE:4534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mochida Pharmaceutical Co Business Description

Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
63GF Score

Get the complete analysis for TSE:4534

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,185.00
Price
円3,675.74
GF Value